Search

Your search keyword '"Furtado, Remo"' showing total 198 results
Start Over Author "Furtado, Remo" Publication Type Academic Journals
198 results on '"Furtado, Remo"'

1. Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trial

Author

de Barros e Silva, Pedro Gabriel Melo, Furtado, Remo H. M., de Alcântara Chaud, Mariana Silveira, Macedo, Ariane Vieira Scarlatelli, Bronhara, Bruna, Damiani, Lucas Petri, Barbosa, Lilian Mazza, Suiama, Mayra Akimi, Ramacciotti, Eduardo, de Aquino Martins, Priscilla, de Oliveira, Aryadne Lyrio, Nunes, Vinicius Santana, Ritt, Luiz Eduardo Fonteles, Rocha, Ana Thereza, Tramujas, Lucas, Santos, Sueli V., Diaz, Dario Rafael Abregu, Viana, Lorena Souza, Melro, Lívia Maria Garcia, Figueiredo, Estêvão Lanna, Neuenschwander, Fernando Carvalho, Dracoulakis, Marianna Deway Andrade, Lima, Rodolfo Godinho Souza Dourado, de Souza Dantas, Vicente Cés, Fernandes, Anne Cristine Silva, Gebara, Otávio Celso Eluf, Hernandes, Mauro Esteves, Queiroz, Diego Aparecido Rios, Veiga, Viviane C., Canesin, Manoel Fernandes, de Faria, Leonardo Meira, Feitosa-Filho, Gilson Soares, Gazzana, Marcelo Basso, Liporace, Idelzuíta Leandro, de Oliveira Twardowsky, Aline, Maia, Lilia Nigro, Machado, Flávia Ribeiro, de Matos Soeiro, Alexandre, Conceição-Souza, Germano Emílio, Armaganijan, Luciana, Guimarães, Patrícia O., Rosa, Regis G., Azevedo, Luciano C. P., Alexander, John H., Avezum, Alvaro, Berwanger, Otávio, Cavalcanti, Alexandre B., and Lopes, Renato D.

Published
2024
Full Text
View/download PDF

2. Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials

Author

Hamidi, Fardin, Anwari, Elaaha, Spaulding, Christian, Hauw-Berlemont, Caroline, Vilfaillot, Aurélie, Viana-Tejedor, Ana, Kern, Karl B., Hsu, Chiu-Hsieh, Bergmark, Brian A., Qamar, Arman, Bhatt, Deepak L., Furtado, Remo H. M., Myhre, Peder L., Hengstenberg, Christian, Lang, Irene M., Frey, Norbert, Freund, Anne, Desch, Steffen, Thiele, Holger, Preusch, Michael R., and Zelniker, Thomas A.

Published
2024
Full Text
View/download PDF

3. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials

Author

Vale, Claire, Godolphin, Peter J, Fisher, David, Horby, Peter W, Kosiborod, Mikhail N, Hochman, Judith S, Webster, Katie, Higgins, Julian P T, Althouse, Andrew D, Berwanger, Otavio, Furtado, Remo H M, Gasparyan, Samvel B, Haynes, Richard, Koch, Gary G, Landray, Martin, Leifer, Eric, Marshall, John, Murthy, Srinivas, Neal, Matthew D, Staplin, Natalie, Diaz, Janet, Sterne, Jonathan A C, and Shankar-Hari, Manu

Published
2024
Full Text
View/download PDF

4. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials

Author

Furtado, Remo H.M., Barros e Silva, Pedro G.M., Fonseca, Henrique A.R., Serpa-Neto, Ary, Correa, Thiago D., Guimarães, Hélio P., Pereira, Adriano J., Olivato, Guilherme B., Zampieri, Fernando G., Lisboa, Thiago, Junqueira, Debora L.M., Lapa, Maura G., Monfardini, Frederico, Damiani, Lucas P., Echenique, Leandro S., Gebara, Otavio E., Hoffman Filho, Conrado R., Polanczyk, Carisi A, Rohde, Luis E., Amazonas, Roberto, Machado, Flávia R., Avezum, Alvaro, Azevedo, Luciano C.P., Veiga, Viviane C., Rosa, Regis G., Lopes, Renato D., Cavalcanti, Alexandre B., and Berwanger, Otavio

Published
2024
Full Text
View/download PDF

6. Abstract 13057: The Role of Ischemic and Bleeding Scores in Patients With Acute Coronary Syndromes Submitted to Coronary Surgical Revascularization During the Same Hospitalization

Author

Nicolau, Jose C, Montero Ribera, Jorge L, Bertolin, Adriadne, Baracioli, Luciano, Giraldez, Roberto, Lima, Felipe G, Andrade, Maria, Castro Vintimilla, Santiago, Salis, Leonardo, Jatene, Fabio, Freitas, Fabiane, Dallan, Luis Alberto Oliveira, Lisboa, Luiz Augusto, Asdrubal Vilca Mejia, Omar, Furtado, Remo, Godoy, Lucas C, and farkouh, michael

Published
2023
Full Text
View/download PDF

7. Abstract 12946: Among Patients With Acute Coronary Syndromes, is the Risk of Hyperglycemia for In-Hospital Mortality Similar in Men and Women?

Author

Nicolau, Jose C, Castro Vintimilla, Santiago A, Rosa, Renato, Bertolin, Adriadne J, Andrade, Maria C, Salis, Leonardo V, Montero Ribera, Jorge L, Quintanilha, Nadia R, Santos, Glaylton S, Baracioli, Luciano M, Giraldez, Roberto R, Lima, Felipe G, Pereira, Cesar C, Nicolau, Andre M, Furtado, Remo H, and Giugliano, Robert P

Published
2023
Full Text
View/download PDF

10. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Kosiborod, Mikhail N, Esterline, Russell, Furtado, Remo H M, Oscarsson, Jan, Gasparyan, Samvel B, Koch, Gary G, Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Buenconsejo, Joan, Langkilde, Anna Maria, Ambery, Philip, Tang, Fengming, Gosch, Kensey, Windsor, Sheryl L, Akin, Emily E, Soares, Ronaldo V P, Moia, Diogo D F, Aboudara, Matthew, Hoffmann Filho, Conrado Roberto, Feitosa, Audes D M, Fonseca, Alberto, Garla, Vishnu, Gordon, Robert A, Javaheri, Ali, Jaeger, Cristiano P, Leaes, Paulo E, Nassif, Michael, Pursley, Michael, Silveira, Fabio Serra, Barroso, Weimar Kunz Sebba, Lazcano Soto, José Roberto, Nigro Maia, Lilia, and Berwanger, Otavio

Published
2021
Full Text
View/download PDF

11. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial

Author

Lopes, Renato D., de Barros e Silva, Pedro Gabriel Melo, Furtado, Remo H.M., Macedo, Ariane Vieira Scarlatelli, Ramacciotti, Eduardo, Damini, Lucas Petri, Bronhara, Bruna, Cavalcanti, Alexandre B., Rosa, Regis G., Azevedo, Luciano C.P., Veiga, Viviane C., Machado, Flávia R, Ritt, Luiz Eduardo, Martins, Priscilla de Aquino, Alexander, John H., Avezum, Alvaro, and Berwanger, Otavio

Published
2021
Full Text
View/download PDF

12. Abstract 10481: The Effect of Current Smoking on Platelet Reactivity Measures by Point-of-Care Methods in Patients Treated With and Without Clopidogrel

Author

Nicolau, Jose C, Salsoso, Rocio, Dalcoquio, Talia, Gurbel, Paul A, Tantry, Udaya, Giugliano, Robert, Nakashima, Carlos A, Franci, Andre, Rizzo, Paulo, menezes, fernando, Guardieiro, Bruno, Scanavini Filho, Marco Antonio, Ferrari, Aline G, Pereira, Cesar, Arantes, Flavia B, Barbosa, Carlos, Bertolin, Adriadne, and Furtado, Remo

Published
2022
Full Text
View/download PDF

14. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization

Author

Nakashima, Carlos A.K., Dallan, Luis A.O., Lisboa, Luiz A.F., Jatene, Fabio B., Hajjar, Ludhmila A., Soeiro, Alexandre M., Furtado, Remo H.M., Dalçoquio, Talia F., Baracioli, Luciano M., Lima, Felipe G., Giraldez, Roberto R.C.V., Silva, Bianca A., Costa, Mateus S.S., Strunz, Celia M.C., Dallan, Luis R.P., Barbosa, Carlos J.D.G., Britto, Flavia A.B., Farkouh, Michael E., Gurbel, Paul A., and Nicolau, Jose C.

Published
2021
Full Text
View/download PDF

15. Platelet Reactivity and Coagulation Markers in Patients with COVID-19

Author

Bertolin, Adriadne J., Dalçóquio, Talia F., Salsoso, Rocío, de M. Furtado, Remo H., Kalil-Filho, Roberto, Hajjar, Ludhmila A., Siciliano, Rinaldo F., Kallás, Esper G., Baracioli, Luciano M., Lima, Felipe G., Giraldez, Roberto R., Cavalheiro-Filho, Cyrillo, Vieira, Alexandra, Strunz, Célia M. C., Giugliano, Robert P., Tantry, Udaya S., Gurbel, Paul A., and Nicolau, José C.

Published
2021
Full Text
View/download PDF

25. Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.

Author

Falcão Dalçóquio, Talia, Alves dos Santos, Mayara, Silva Alves, Leandro, Brito Arantes, Flávia Bittar, Ferreira-Santos, Larissa, Pinto Brandão Rondon, Maria Urbana, Furtado, Remo Holanda M., Ferrari, Aline Gehlen, Rizzo, Paulo Roberto Genestreti, Salsoso, Rocio, Franci, Andre, Moreira Baracioli, Luciano, de Nazare Nunes Alves, Maria Janieire, Eduardo Negrão, Carlos, and Carlos Nicolau, José

Subjects
MYOCARDIAL infarction, CLINICAL trials, BLOOD platelets, EXERCISE tests, CARDIOVASCULAR diseases risk factors, ADENOSINE diphosphate
Abstract

Exercise training (ET) can lower platelet reactivity in patients with cardiovascular risk factors. However, the effects of ET on platelet reactivity in higher-risk patients is unknown. The aim of this study was to evaluate the effects of ET on platelet reactivity in patients with recent myocardial infarction (MI). Ninety patients were randomly assigned 1 month post-MI to the intervention (patients submitted to a supervised ET program) or control group. All patients were on dual antiplatelet therapy (DAPT). Platelet reactivity by VerifyNow-P2Y12 (measured by P2Y12 reaction units - PRUs) test was determined at baseline and at the end of 14 ± 2 weeks of follow-up at rest (primary endpoint), and multiplate electrode aggregometry (MEA) adenosine diphosphate (ADP) and aspirin (ASPI) tests were performed immediately before and after the maximal cardiopulmonary exercise test (CPET) at the same time points (secondary endpoints). Sixty-five patients (mean age 58.9 ± 10 years; 73.8% men; 60% ST elevation MI) completed follow-up (control group, n = 31; intervention group, n = 34). At the end of the follow-up, the mean platelet reactivity was 172.8 ± 68.9 PRUs and 166.9 ± 65.1 PRUs for the control and intervention groups, respectively (p = .72). Platelet reactivity was significantly increased after the CPET compared to rest at the beginning and at the end of the 14-week follow-up (among the intervention groups) by the MEA-ADP and MEA-ASPI tests (p < .01 for all analyses). In post-MI patients on DAPT, 14 weeks of supervised ET did not reduce platelet reactivity. Moreover, platelet reactivity was increased after highintensity exercise (ClinicalTrials.gov: NCT02958657; https://clinicaltrials.gov/ct2/show/NCT02958657). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

Author

Bonaca, Marc P., Wiviott, Stephen D., Zelniker, Thomas A., Mosenzon, Ofri, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Goodrich, Erica L., De Mendonca Furtado, Remo Holanda, Wilding, John P.H., Cahn, Avivit, Gause-Nilsson, Ingrid A.M., Johanson, Per, Fredriksson, Martin, Johansson, Peter A., Langkilde, Anna Maria, Raz, Itamar, and Sabatine, Marc S.

Published
2020
Full Text
View/download PDF

27. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Author

Zelniker, Thomas A., Bonaca, Marc P., Furtado, Remo H.M., Mosenzon, Ofri, Kuder, Julia F., Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Budaj, Andrzej, Kiss, Robert G., Padilla, Francisco, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2020
Full Text
View/download PDF

29. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Author

Kato, Eri T., Silverman, Michael G., Mosenzon, Ofri, Zelniker, Thomas A., Cahn, Avivit, Furtado, Remo H.M., Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Bonaca, Marc P., Ruff, Christian T., Desai, Akshay S., Goto, Shinya, Johansson, Peter A., Gause-Nilsson, Ingrid, Johanson, Per, Langkilde, Anna Maria, Raz, Itamar, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

30. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

Author

Furtado, Remo H.M., Bonaca, Marc P., Raz, Itamar, Zelniker, Thomas A., Mosenzon, Ofri, Cahn, Avivit, Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Ruff, Christian T., Nicolau, Jose C., Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Langkilde, Anna Maria, Sabatine, Marc S., and Wiviott, Stephen D.

Published
2019
Full Text
View/download PDF

31. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Author

Zelniker, Thomas A., Wiviott, Stephen D., Raz, Itamar, Im, KyungAh, Goodrich, Erica L., Furtado, Remo H.M., Bonaca, Marc P., Mosenzon, Ofri, Kato, Eri T., Cahn, Avivit, Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., and Sabatine, Marc S.

Published
2019
Full Text
View/download PDF

33. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study

Author

Furtado, Remo Holanda de Mendonça, Giugliano, Robert Patrick, Strunz, Celia Maria Cassaro, Filho, Cyrillo Cavalheiro, Ramires, José Antonio Franchini, Filho, Roberto Kalil, Neto, Pedro Alves Lemos, Pereira, Alexandre Costa, Rocha, Tânia Rúbia, Freire, Beatriz Tonon, D’Amico, Elbio Antonio, and Nicolau, José Carlos

Published
2016
Full Text
View/download PDF

34. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.

Author

Furtado, Remo H.M., Juliasz, Marcela G., Chiu, Felipe Y.J., Bastos, Livia B.C., Dalcoquio, Talia F., Lima, Felipe G., Rosa, Renato, Caporrino, Cesar A., Bertolin, Adriadne, Genestreti, Paulo R.R., Ribeiro, Andre S., Andrade, Maria Carolina, Giraldez, Roberto R.C.V., Baracioli, Luciano M., Zelniker, Thomas A., and Nicolau, Jose C.

Subjects
ACUTE coronary syndrome, VENTRICULAR ejection fraction, MORTALITY risk factors, HOSPITAL admission & discharge
Abstract

Aims: Left ventricular ejection fraction (LVEF) ≤ 40% is a well‐established risk factor for mortality after acute coronary syndromes (ACS). However, the long‐term prognostic impact of mildly reduced ejection fraction (EF) (LVEF 41–49%) after ACS remains less clear. Methods and results: This was a retrospective study enrolling patients admitted with ACS included in a single‐centre databank. LVEF was assessed by echocardiography during index hospitalization. Patients were divided in the following categories according to LVEF: normal (LVEF ≥ 50%), mildly reduced (LVEF 41–49%), and reduced (LVEF ≤ 40%). The endpoint of interest was all‐cause death after hospital discharge. A multivariable Cox model was used to adjust for confounders. A total of 3200 patients were included (1952 with normal EF, 375 with mildly reduced EF, and 873 with reduced EF). The estimated cumulative incidence rates of mortality at 10 years for patients with normal, mildly reduced, and reduced EF were 24.8%, 33.5%, and 41.3%, respectively. After adjustments, the presence of reduced EF was associated with higher mortality compared with normal EF [adjusted hazard ratio (HR) 1.64; 95% confidence interval (CI) 1.36–1.96; P < 0.001], as was mildly reduced EF compared with normal EF (adjusted HR 1.33; 95% CI 1.05–1.68; P = 0.019). The presence of reduced EF was not associated with a statistically significantly higher mortality compared with mildly reduced EF (adjusted HR 1.23; 95% CI 0.96–1.57; P = 0.095). Conclusions: In patients with ACS, mildly reduced EF measured in the acute phase was associated with higher long‐term mortality compared with patients with normal EF. These data emphasize the importance of anti‐remodelling therapies for ACS patients who have LVEF in the mildly reduced range. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial.

Author

Dalçóquio, Talia Falcão, Alves dos Santos, Mayara, Silva Alves, Leandro, Bittar Brito Arantes, Flávia, Ferreira-Santos, Larissa, Pinto Brandão Rondon, Maria Urbana, Furtado, Remo Holanda M, Gehlen Ferrari, Aline, Genestreti Rizzo, Paulo Roberto, Salsoso, Rocio, Franci, Andre, Moreira Baracioli, Luciano, de Nazare Nunes Alves, Maria Janieire, Negrão, Carlos Eduardo, and Nicolau, José Carlos

Subjects
MYOCARDIAL infarction, CLINICAL trials, BLOOD platelets, CARDIOVASCULAR diseases risk factors, EXERCISE tests, PLATELET aggregation inhibitors
Abstract

Exercise training (ET) can lower platelet reactivity in patients with cardiovascular risk factors. However, the effects of ET on platelet reactivity in higher-risk patients is unknown. The aim of this study was to evaluate the effects of ET on platelet reactivity in patients with recent myocardial infarction (MI). Ninety patients were randomly assigned 1 month post-MI to the intervention (patients submitted to a supervised ET program) or control group. All patients were on dual antiplatelet therapy (DAPT). Platelet reactivity by VerifyNow-P2Y12 (measured by P2Y12 reaction units – PRUs) test was determined at baseline and at the end of 14 ± 2 weeks of follow-up at rest (primary endpoint), and multiplate electrode aggregometry (MEA) adenosine diphosphate (ADP) and aspirin (ASPI) tests were performed immediately before and after the maximal cardiopulmonary exercise test (CPET) at the same time points (secondary endpoints). Sixty-five patients (mean age 58.9 ± 10 years; 73.8% men; 60% ST elevation MI) completed follow-up (control group, n = 31; intervention group, n = 34). At the end of the follow-up, the mean platelet reactivity was 172.8 ± 68.9 PRUs and 166.9 ± 65.1 PRUs for the control and intervention groups, respectively (p =.72). Platelet reactivity was significantly increased after the CPET compared to rest at the beginning and at the end of the 14-week follow-up (among the intervention groups) by the MEA-ADP and MEA-ASPI tests (p <.01 for all analyses). In post-MI patients on DAPT, 14 weeks of supervised ET did not reduce platelet reactivity. Moreover, platelet reactivity was increased after high-intensity exercise (ClinicalTrials.gov: NCT02958657; ). What is the context? Platelet reactivity is reduced after exercise training in healthy individuals and patients with cardiovascular risk factors, but the effect in higher-risk patients is unknown. High-intensity exercise in untrained individuals increases platelet reactivity. The effect of dual antiplatelet therapy in inhibiting exercise-induced hyperreactivity is poorly understood. What's new? Exercise training did not reduce platelet reactivity in post-myocardial infarction patients. High-intensity exercise increased platelet reactivity in post-myocardial infarction patients on dual antiplatelet therapy. Exercise training did not attenuate the exercise-induced increase in platelet reactivity. What's the impact? The study suggests that strenuous exercise, if indicated, should be applied carefully to patients with high risk of recurrent ischemic events, even if on optimal medical therapy and after being trained. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial.

Author

Fonseca, Henrique Andrade R, Furtado, Remo Holanda M, Zimerman, André, Lemos, Pedro A, Franken, Marcelo, Monfardini, Frederico, Pedrosa, Rodrigo P, Patriota, Rodrigo de Lemos S, Passos, Luiz Carlos S, Dall'Orto, Frederico Toledo C, Filho, Conrado R Hoffmann, Nascimento, Bruno Ramos, Baldissera, Felipe A, Pereira, Cesar Augusto C, Caramori, Paulo Ricardo A, Andrade, Pedro Beraldo de, Esteves, Carlos, Salim, Elke Ferreira, Silva, Jefferson Henrique da, and Pedro, Izabela Chave

Subjects
ACUTE coronary syndrome, INFLUENZA vaccines, ANGINA pectoris, MYOCARDIAL infarction, HEART failure
Abstract

Aims To evaluate whether a strategy of double-dose influenza vaccination during hospitalization for an acute coronary syndrome (ACS) compared with standard-dose outpatient vaccination (as recommended by current guidelines) would further reduce the risk of major cardiopulmonary events. Methods and results Vaccination against Influenza to Prevent cardiovascular events after Acute Coronary Syndromes (VIP-ACS) was a pragmatic, randomized, multicentre, active-comparator, open-label trial with blinded outcome adjudication comparing two strategies of influenza vaccination following an ACS: double-dose quadrivalent inactivated vaccine before hospital discharge vs. standard-dose quadrivalent inactivated vaccine administered in the outpatient setting 30 days after randomization. The primary outcome was a hierarchical composite of all-cause death, myocardial infarction, stroke, unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory causes, analysed by the win ratio method. Patients were followed for 12 months. During two influenza seasons, 1801 participants were included at 25 centres in Brazil. The primary outcome was not different between groups, with 12.7% wins in-hospital double-dose vaccine group and 12.3% wins in the standard-dose vaccine group {win ratio: 1.02 [95% confidence interval (CI): 0.79–1.32], P = 0.84}. Results were consistent for the key secondary outcome, a hierarchical composite of cardiovascular death, myocardial infarction and stroke [win ratio: 0.94 (95% CI: 0.66–1.33), P = 0.72]. Time-to-first event analysis for the primary outcome showed results similar to those of the main analysis [hazard ratio 0.97 (95% CI: 0.75–1.24), P = 0.79]. Adverse events were infrequent and did not differ between groups. Conclusion Among patients hospitalized with an ACS, double-dose influenza vaccination before discharge did not reduce cardiopulmonary outcomes compared with standard-dose vaccination in the outpatient setting. Clinical Trial Registration ClinicalTrials.gov number: NCT04001504 [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction.

Author

Genestreti, Paulo R. Rizzo, Furtado, Remo H. M., Salsoso, Rocio, Dalçóquio, Talia F., Franci, Andre, Menezes, Fernando R., Caporrino, Cesar, Ferrari, Aline G., Nakashima, Carlos A. K., Scanavini Filho, Marco A., Lima, Felipe G., Giraldez, Roberto R. C. V., Baracioli, Luciano M., and Nicolau, Jose C.

Subjects
*MYOCARDIAL infarction, *TYPE 2 diabetes, *ASPIRIN, *PLATELET aggregation inhibitors, *BLOOD platelet aggregation, *PEOPLE with diabetes
Abstract

Background: The management of acute myocardial infarction (AMI) presents several challenges in patients with diabetes, among them the higher rate of recurrent thrombotic events, hyperglycemia and risk of subsequent heart failure (HF). The objective of our study was to evaluate effects of DPP-4 inhibitors (DPP-4i) on platelet reactivity (main objective) and cardiac risk markers. Methods: We performed a single-center double-blind randomized trial. A total of 70 patients with type 2 diabetes (T2DM) with AMI Killip ≤2 on dual-antiplatelet therapy (aspirin plus clopidogrel) were randomized to receive sitagliptin 100 mg or saxagliptin 5 mg daily or matching placebo. Platelet reactivity was assessed at baseline, 4 days (primary endpoint) and 30 days (secondary endpoint) after randomization, using VerifyNow Aspirin™ assay, expressed as aspirin reaction units (ARUs); B-type natriuretic peptide (BNP) in pg/mL was assessed at baseline and 30 days after (secondary endpoint). Results: Mean age was 62.6 ± 8.8 years, 45 (64.3%) male, and 52 (74.3%) of patients presented with ST-segment elevation MI. For primary endpoint, there were no differences in mean platelet reactivity (p = 0.51) between the DPP-4i (8.00 {−65.00; 63.00}) and placebo (−14.00 {−77.00; 52.00}) groups, as well in mean BNP levels (p = 0.14) between DPP-4i (−36.00 {−110.00; 15.00}) and placebo (−13.00 {−50.00; 27.00}). There was no difference between groups in cardiac adverse events. Conclusions: DPP4 inhibitor did not reduce platelet aggregation among patients with type 2 diabetes hospitalized with AMI. Moreover, the use of DPP-4i did not show an increase in BNP levels or in the incidence of cardiac adverse events. These findings suggests that DPP-4i could be an option for management of T2DM patients with acute MI. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.

Author

Bonaca, Marc P., Morrow, David A., Bergmark, Brian A., Berg, David D., Lima, Joao A.C., Hoffmann, Udo, Kato, Yoko, Lu, Michael T., Kuder, Julia, Murphy, Sabina A., Spinar, Jindrich, Oude Ophuis, Ton, Kiss, Róbert G., Lopez-Sendon, Jose, Averkov, Oleg, Wheatcroft, Stephen B., Kubica, Jacek, Carlos Nicolau, Jose, Furtado, Remo H.M., and Abuhatzira, Liron

Published
2022
Full Text
View/download PDF

39. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.

Author

Furtado, Remo H.M., Raz, Itamar, Goodrich, Erica L., Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A., McGuire, Darren K., Wilding, John P.H., Aylward, Philip, Dalby, Anthony J, Dellborg, Mikael, Dimulescu, Doina, Nicolau, José C., Oude Ophuis, Anthonius J.M., Cahn, Avivit, Mosenzon, Ofri, Gause-Nilsson, Ingrid, Langkilde, Anna Maria, Sabatine, Marc S., and Wiviott, Stephen D.

Subjects
*HEART failure, *TYPE 2 diabetes, *BLOOD pressure, *LEG amputation, *CARDIOVASCULAR diseases risk factors, *DAPAGLIFLOZIN
Abstract

Background: Dapagliflozin improved heart failure and kidney outcomes in patients with type 2 diabetes (T2DM) with or at high risk for atherosclerotic cardiovascular disease in the DECLARE-TIMI 58 trial (Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in Myocardial Infarction 58). Here, the aim was to analyze the efficacy and safety of dapagliflozin stratified according to baseline systolic blood pressure (SBP).Methods: The DECLARE-TIMI 58 trial randomly assigned patients with T2DM and either previous atherosclerotic cardiovascular disease or atherosclerotic cardiovascular disease risk factors to dapagliflozin or placebo. Patients were categorized by baseline SBP levels: <120, 120 to 129, 130 to 139, 140 to 159, and ≥160 mm Hg (normal, elevated, stage 1, stage 2, and severe hypertension, respectively). Efficacy outcomes of interest were hospitalization for heart failure and a renal-specific composite outcome (sustained decrease in estimated glomerular filtration rate by 40%, progression to end-stage renal disease, or renal death). Safety outcomes included symptoms of volume depletion, lower extremity amputations, and acute kidney injury.Results: The trial comprised 17 160 patients; mean age, 64.0±6.8 years; 37.4% women; median duration of T2DM, 11 years; 40.6% with prevalent cardiovascular disease. Overall, dapagliflozin reduced SBP by 2.4 mm Hg (95% CI, 1.9-2.9; P<0.0001) compared with placebo at 48 months. The beneficial effects of dapagliflozin on hospitalization for heart failure and renal outcomes were consistent across all baseline SBP categories, with no evidence of modification of treatment effect (Pinteractions=0.28 and 0.52, respectively). Among normotensive patients, the hazard ratios were 0.66 (95% CI, 0.42-1.05) and 0.39 (95% CI, 0.19-0.78), respectively, for hospitalization for heart failure and the renal-specific outcome. Events of volume depletion, amputation, and acute kidney injury did not differ with dapagliflozin overall or within any baseline SBP group.Conclusions: In patients with T2DM with or at high atherosclerotic cardiovascular disease risk, dapagliflozin reduced risk for hospitalization for heart failure and renal outcomes regardless of baseline SBP, with no difference in adverse events of interest at any level of baseline SBP. These results indicate that dapagliflozin provides cardiorenal benefits in patients with T2DM at high atherosclerotic cardiovascular disease risk independent of baseline blood pressure.Registration: URL: https://www.Clinicaltrials: gov; Unique identifier: NCT01730534. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.

Author

Furtado, Remo H M, Berwanger, Otavio, Fonseca, Henrique A, Corrêa, Thiago D, Ferraz, Leonardo R, Lapa, Maura G, Zampieri, Fernando G, Veiga, Viviane C, Azevedo, Luciano C P, Rosa, Regis G, Lopes, Renato D, Avezum, Alvaro, Manoel, Airton L O, Piza, Felipe M T, Martins, Priscilla A, Lisboa, Thiago C, Pereira, Adriano J, Olivato, Guilherme B, Dantas, Vicente C S, and Milan, Eveline P

Subjects
*COVID-19, *AZITHROMYCIN, *HOSPITAL patients, *ACUTE kidney failure, *CLINICAL trials, *VIRAL pneumonia, *MEDICAL quality control, *LENGTH of stay in hospitals, *RESEARCH, *COMBINATION drug therapy, *RESEARCH methodology, *ANTIVIRAL agents, *EVALUATION research, *MEDICAL cooperation, *TREATMENT effectiveness, *COMPARATIVE studies, *RANDOMIZED controlled trials, *RESPIRATORY therapy, *EPIDEMICS, *HYDROXYCHLOROQUINE
Abstract

Background: The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19.Methods: We did an open-label, randomised clinical trial at 57 centres in Brazil. We enrolled patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation. Patients were randomly assigned (1:1) to azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care or to standard of care without macrolides. All patients received hydroxychloroquine (400 mg twice daily for 10 days) because that was part of standard of care treatment in Brazil for patients with severe COVID-19. The primary outcome, assessed by an independent adjudication committee masked to treatment allocation, was clinical status at day 15 after randomisation, assessed by a six-point ordinal scale, with levels ranging from 1 to 6 and higher scores indicating a worse condition (with odds ratio [OR] greater than 1·00 favouring the control group). The primary outcome was assessed in all patients in the intention-to-treat (ITT) population who had severe acute respiratory syndrome coronavirus 2 infection confirmed by molecular or serological testing before randomisation (ie, modified ITT [mITT] population). Safety was assessed in all patients according to which treatment they received, regardless of original group assignment. This trial was registered at ClinicalTrials.gov, NCT04321278.Findings: 447 patients were enrolled from March 28 to May 19, 2020. COVID-19 was confirmed in 397 patients who constituted the mITT population, of whom 214 were assigned to the azithromycin group and 183 to the control group. In the mITT population, the primary endpoint was not significantly different between the azithromycin and control groups (OR 1·36 [95% CI 0·94-1·97], p=0·11). Rates of adverse events, including clinically relevant ventricular arrhythmias, resuscitated cardiac arrest, acute kidney failure, and corrected QT interval prolongation, were not significantly different between groups.Interpretation: In patients with severe COVID-19, adding azithromycin to standard of care treatment (which included hydroxychloroquine) did not improve clinical outcomes. Our findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19.Funding: COALITION COVID-19 Brazil and EMS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results